Quest for Ideal Composite Biomarkers for Response to Immunotherapies.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32759359.
- Also identified by DOI 10.1158/1078-0432.CCR-20-2321.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the CheckMate 275 study, composite biomarkers appear to better predict response to immunotherapy over individual ones. Nevertheless, the path forward needs consensus guidelines for biomarker interpretation. Thereafter, prospective validation with real-time, serial biospecimen collection along with the development of composite biomarker models leads to the goal of personalized therapy.<i>See related article by Galsky et al., p. 5120</i>.
Medical subject headings
- Carcinoma
- Nivolumab